Core Insights - The company reported preliminary unaudited revenue for Q4 and full year 2025, indicating strong growth in both periods [1][4]. Q4 2025 Performance - Q4 2025 revenue is expected to be approximately $11.3 million, reflecting a growth of about 37% compared to the same period last year [2][8]. - Recurring revenue for Q4 2025 is anticipated to be around $4.6 million, showing a growth of approximately 10% year-over-year [2]. - The company achieved a record placement of 16 new Growth Direct systems and completed the validation of three customer systems in Q4 [2]. Full Year 2025 Performance - Total revenue for the full year 2025 is projected to be approximately $33.6 million, representing a growth of about 20% compared to the previous year [3][8]. - Recurring revenue for the full year is expected to be around $17.8 million, indicating a growth of approximately 15% year-over-year [3]. - The company placed a total of 28 new Growth Direct systems and validated 18 customer systems throughout 2025, bringing the cumulative total to 190 systems placed globally with 155 validated [3]. Management Commentary - The President and CEO expressed satisfaction with the record results for Q4, which exceeded the raised guidance from November [4]. - The company is positioned for continued growth in 2026, supported by a strong execution track record and advancements in its strategic partnership with MilliporeSigma [4]. Upcoming Events - The company is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, with a live webcast available for investors [6].

Core Viewpoint - Rapid Micro Biosystems, Inc. reported a 10% increase in total revenue for Q2 2025, driven by strong service revenue growth and reaffirmed its full-year revenue guidance of at least $32 million [2][7][9]. Financial Performance - Total revenue for Q2 2025 was $7.3 million, up from $6.6 million in Q2 2024, with service revenue increasing by 18% to $2.5 million and product revenue rising by 6% to $4.8 million [3][6][9]. - Recurring revenue grew by 15% to $4.4 million compared to $3.8 million in Q2 2024 [3][9]. - Gross margin improved to 4%, a seven-percentage point increase from the negative 3% in Q2 2024 [4][9]. Cost and Expenses - Total cost of revenue increased by 3% to $7.0 million in Q2 2025, while total operating expenses decreased by 6% to $12.4 million [4][5]. - General and administrative expenses rose by 4%, while research and development and sales and marketing expenses both decreased by 14% [5]. Net Loss and Cash Position - The net loss for Q2 2025 was $11.9 million, an improvement from the $12.6 million loss in Q2 2024, with net loss per share decreasing from $0.29 to $0.27 [6][9]. - As of June 30, 2025, the company had approximately $32 million in cash, cash equivalents, short-term investments, and restricted cash [6][21]. Loan Facility - The company announced a new five-year, $45 million term loan facility, with $20 million funded upfront, which is expected to strengthen its financial position [2][10].